Investing in Biotech with Verdad Capital

The podcast explores value and fundamental quant investing within the biotech sector, guided by insights from Dan Rasmussen and Greg Obenshain of Verdad Capital. The discussion centers on a paper by the guests that challenges conventional value investing approaches by incorporating factors beyond traditional financial statements. A key insight involves the significance of specialist investor ownership as a quality metric and alpha signal. The conversation further investigates the role of shorting in biotech, emphasizing risk management and diversification, and examines the predictive power of company insider buying, particularly among CFOs and the broader C-suite. The hosts also explore a value metric based on company spend, the momentum within specific trial categories, and the unique challenges and opportunities within the biotech industry.